Design Therapeutics, Inc. Insider Trading

DSGN

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Mar 2024.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Mar 2024

Mar 25, 2024

Get an email when DSGN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 13, 2025	Arsani William Director	SoldNo plan 2 parts	562,627	$5.25 average	$2.95M	13%	Form 4
Dec 18, 2024	Deepa Prasad Director	SoldNo plan	3,806	$6.27	24K	16%	Form 4

Aug 13, 2025No plan
Arsani William
Director · sold 562,627 at avg $5.25
$2.95M
13% of stake
Dec 18, 2024No plan
Deepa Prasad
Director · sold 3,806 at $6.27
24K
16% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DSGN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DSGN

CompareIntrinsic value

TENXTenax Therapeutics Inc.

$1.81-1.63%10

LEXXLexaria Bioscience Corp.

$4.07+0.99%10

PRPHProPhase Labs Inc.

$0.01-42.00%0

CBIOCrescent Biopharma, Inc.

$13.42+2.76%50

OGNOrganon & Co.

$13.83-0.14%28

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

BCYCBicycle Therapeutics PLC

$3.72+1.36%40

BMYBristol-Myers Squibb Company

$64.20+4.04%61

Held by ETFs

DSGN is in 22 US ETFs. The largest of them, with DSGN's weight in each:

Spot a number that looks wrong? Check it in DSGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DSGN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.